Amylyx Pharmaceuticals
AMLX
170 hedge funds and large institutions have $1.08B invested in Amylyx Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 48 reducing their positions, and 16 closing their positions.
113% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 16
42% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 48
10% more funds holding
Funds holding: 154 → 170 (+16)
6.26% more ownership
Funds ownership: 81.19% → 87.46% (+6.3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less capital invested
Capital invested by funds: $1.18B → $1.08B (-$97.7M)
17% less call options, than puts
Call options by funds: $31.6M | Put options by funds: $38.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$29.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$26.6M |
| 3 |
SC
Samlyn Capital
New York
|
+$24.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$19.7M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$46.2M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$25.5M |
| 3 |
DM
Deerfield Management
New York
|
-$22.7M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.9M |
| 5 |
D.E. Shaw & Co
New York
|
-$17.5M |
AMLX Hedge Fund Activity: Q3 2023 in Review
170 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q3 2023, worth a combined $1.08B — down 8.3% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AMLX positions and 16 closed out — a net gain of 18 holders — while 68 added to existing stakes and 48 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $29.5M. The largest seller was Perceptive Advisors, cutting an estimated $46.2M.
- 170 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q3 2023, up from 154 in Q2 2023.
- Funds reported $1.08B of Amylyx Pharmaceuticals stock for Q3 2023, down 8.3% quarter-over-quarter.
- 34 funds opened new Amylyx Pharmaceuticals positions in Q3 2023 and 16 closed out, a net change of +18 holders.
- The largest Amylyx Pharmaceuticals buyer in Q3 2023 was Stonepine Capital Management, an estimated $29.5M added.
- The largest Amylyx Pharmaceuticals seller in Q3 2023 was Perceptive Advisors, an estimated $46.2M sold.
Based on aggregated 13F filings for Q3 2023.